arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Nkarta, Inc.

NKTX
$2.39 ▲ +0.10 (+4.60%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
30 Visible periods
19 Metrics
Peer-ranked Benchmarks
Price Chart
32
Health
Poor
Bearish
auto_awesome

Analytical Summary

Nkarta, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $177.5M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -8.5%
FCF / Share $-0.39
Trailing P/E
Price / Book 0.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

30-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↑ +100.0%
Net Income Profit after all expenses
$-27.83M
↑ +13.0%
FCF / Share Free cash flow per share
$-0.39
↑ +5.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
22
Cash Quality
58

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 30 quarters